We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Human Genome Sciences has completed the enrollment and initial dosing of patients
in a Phase II clinical trial of HGS-ETR1 in patients with advanced colorectal
cancer.
Teva Pharmaceutical Industries and H. Lundbeck A/S has announced that the
European Commission issued a marketing authorization valid throughout the
European Union for Azilect (rasagiline 1 mg, once daily), for the treatment
of Parkinson's disease (PD) both as monotherapy in patients with early PD
and as adjunct treatment in moderate-to-advanced disease.
Curis, a therapeutic drug development company, has announced that Curis scientists
have demonstrated that a small molecule drug compound can induce hair growth
in a preclinical model.
Cubist Pharmaceuticals has announced that all of the enrolled patients in
the Cubicin endocarditis/bacteremia study have completed the treatment phase
of the trial, and the remaining patients are now in the follow-up period.
Targeted Genetics has reported preliminary results from a Phase I trial of
tgAAC09, an investigational recombinant adeno-associated viral vector (rAAV)-based
HIV/AIDS vaccine candidate, enrolling healthy volunteers who are not infected
with HIV.